Lactiga Us Inc.
Publicly observedNorth Brunswick, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | North Brunswick | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Lactiga Us Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | GCKSALSGA2T6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant10 Sept 2026Publicly observed
NIH SBIR/STTR award: Preclinical Development of LCTG-001, a Human Secretory IgA Replacement Therapy for CVID Patients
USD 969,219.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of sIgA from human milk as a therapeutic for Inflammatory bowel disease
USD 303,427.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant24 Jan 2025Publicly observed
NIH SBIR/STTR award: Preclinical Development of LCTG-001, a Human Secretory IgA Replacement Therapy for CVID Patients
USD 304,629.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.